BioBots

biobots.io

BioBots is building tools to design and engineer life. Our goals are to cure disease, eliminate the organ waiting list, reverse climate change, and live on other planets. Our first products are 3D bioprinters, software, and bioinks that print 3D living tissues one layer at a time.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

DESIGN THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ITS GENETAC™ SMALL MOLECULE, DT-168, FOR THE TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY

Globenewswire | April 25, 2023

news image

Design Therapeutics, Inc. a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orl...

Read More

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

news image

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More

Industrial Impact, Medical

BIOVAXYS AND PROCARE HEALTH EXECUTE US DISTRIBUTION AGREEMENT FOR PAPILOCARE GEL AND ORAL IMMUNOCAPS

BioVaxys Technology Corp. | December 20, 2022

news image

BioVaxys Technology Corp. and Procare Health Iberia, of Barcelona, Spain announced that they have finalized and executed the United States Distribution Agreement for Papilocare® and Oral Immunocaps©. Following the binding Term Sheet executed by the two companies in early October 2022, the Distribution Agreement finalized all remaining aspects of the transaction. Developed by Procare Health, Papilocare® is the world's first and only patented vaginal gel product wit...

Read More

MedTech

AMPEL BIOSOLUTIONS' PRECISION MEDICINE BREAKTHROUGH PREDICTS DRUG OPTIONS WITH RNA ANALYTICS & MACHINE LEARNING

AMPEL BioSolutions | July 07, 2022

news image

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...

Read More
news image

Medical, Industry Outlook

DESIGN THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ITS GENETAC™ SMALL MOLECULE, DT-168, FOR THE TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY

Globenewswire | April 25, 2023

Design Therapeutics, Inc. a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orl...

Read More
news image

DYNAVAX AND SINOVAC PARTNER TO DEVELOP COVID-19 VACCINE CANDIDATE

BioSpace | April 16, 2020

California-based Dynavax Technologies has entered the race alongside Sinovac Biotech to develop a vaccine candidate against COVID-19. The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018. Dynavax’s CpG 1018 is the adjuvant used in its Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration in ...

Read More
news image

Industrial Impact, Medical

BIOVAXYS AND PROCARE HEALTH EXECUTE US DISTRIBUTION AGREEMENT FOR PAPILOCARE GEL AND ORAL IMMUNOCAPS

BioVaxys Technology Corp. | December 20, 2022

BioVaxys Technology Corp. and Procare Health Iberia, of Barcelona, Spain announced that they have finalized and executed the United States Distribution Agreement for Papilocare® and Oral Immunocaps©. Following the binding Term Sheet executed by the two companies in early October 2022, the Distribution Agreement finalized all remaining aspects of the transaction. Developed by Procare Health, Papilocare® is the world's first and only patented vaginal gel product wit...

Read More
news image

MedTech

AMPEL BIOSOLUTIONS' PRECISION MEDICINE BREAKTHROUGH PREDICTS DRUG OPTIONS WITH RNA ANALYTICS & MACHINE LEARNING

AMPEL BioSolutions | July 07, 2022

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us